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Nowadays studies have shown that liver fibrosis is a reversible process. Theraupetic target on 
hepatic stellate cell (HSC) through inhibition of fibrotic signaling transduction is one of the way 
to treat liver fibrosis (e.g. pentoxifylline). APRI index, one of the indirect marker of liver fibrosis, 
had shown significant correlation (Spearman correlation  = 0.7) with liver fibrosis degree in 
hepatitis B and C. This study was aimed to evaluate the effect of pentoxifylline treatment in 4 
weeks for liver fibrosis measured by APRI index. We conducted clinical trial on eleven chronic 
hepatitis B patients from Adam Malik Hospital Medan, with positive HBsAg at least 6 months 
after follow up. They were treated with pentoxifylline for 4 weeks. Before and after treatment, 
APRI index was measured. The result showed a decrease of ALT (64.64±49.61 vs 50.64±26.13; 
p=0.28), but AST and APRI index increased (91.82± 100.16 vs 97.91±146.75; p=0.79) and 
(1.17±1.07 vs 1.31±1.84; p=0.96) respectively. It was concluded that the effect of pentoxifylline 
as antifibrotic in the liver measured by APRI index was not proven. It was shown that APRI 
index increased after 4 weeks treatment of pentoxifylline. 
 
 
 
Chronic hepatitis B is an important health 
issue in the world. Approximately 2 billion people in 
the world has been exposed to hepatitis B virus and 
about 400 million of them had suffered from chronic 
hepatitis B (Lok & McMahon, 2007). Approximately 
15 – 40% of chronic hepatitis B patient will be 
cirrhotic and end stage liver disease (Maddrey, 2000; 
Gines et al., 2004). Cirrhotic and end stage liver 
disease caused by the development of liver fibrosis in 
chronic liver damage, concomitantly occur with 
excessive deposition of extracellular matrix (ECM) in 
the liver, and  it will change the architecture of the 
liver and also develop  regeneration nodules (Bataller 
& Brenner, 2005). Nowadays studies have shown 
reversible process of liver fibrosis (Hammel et al., 
2001; Arthur, 2002; Pares et al., 1986; Dixon et al, 2004; 
Bataller & Brenner, 2005). Experimental studies in 
animal have shown that theraupetic target on hepatic 
stellate cell (HSC) can prevent the progressivity of 
liver fibrosis (Wu & Zern, 2000). Neutralization of 
HSC responded through inhibition of fibrotic 
signaling transduction is one of the way that 
probably provide benefits to liver fibrosis treatment 
and pentoxifylline is one of the drugs working by 
that way (Preaux et al., 1997;  Mallat et al., 1995).   
 The expandable knowledge of the liver 
fibrosis process has resulted in noninvasive test of 
liver fibrosis by direct and indirect biomarker 
(Kelleher & Afdhal, 2000). Among indirect marker 
was APRI index that several study had shown the 
significant correlation (Spearman correlation =0.7) 
between APRI index and liver fibrosis degree in 
hepatitis B and C (Kelleher & Afdhal, 2000; Shin et al., 
2008). To the best of our knowledge, there is no data 
on the influence of pentoxifylline to biomarker of 
liver fibrosis, especially APRI index. In that reason 
we perform study on the influence of pentoxifylline 
to APRI index in chronic hepatitis B. 
  
MATERIALS AND METHODS 
 
Patients 
 The patients were in-patient and out-patient 
chronic hepatitis B during February – August 2008 in 
Adam Malik Hospital Medan, with positive HBsAg 
at least 6 months after follow up (based on medical 
record). Clinical examination was performed 
concomitantly  with  routine  blood,  liver  and   renal  
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function test and liver USG. The patients were 
included in the study provided their ages were more 
than 18 years and they agreed to join the study by 
informed consent. The patients were excluded from 
the study if they had history of cerebral and retinal 
bleeding, angina pectoris, less than 2 weeks post 
operation, had been using  theophylline, cimetidine, 
warfarin and experienced decompensated cirrhotic. 
 
Study design  
This study was a clinical trial with pre dan 
post test design. The aim of the study was to examine 
the decrease of APRI index in chronic hepatitis B 
patients after 4 weeks treatment with 400 mg tid 
pentoxifylline and it would be used to decide the use 
of pentoxifylline as one of the antifibrotic agents in 
chronic liver disease.   
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Statistical analysis 
 To compare the decrease of APRI index 
before and after 4 weeks treatment of pentoxifylline, t 
test analysis was used for the data with normal 
distribution and Wilcoxon test for those with 
abnormal distribution. 
 
RESULTS 
 
1. Pre pentoxifylline treatment    
 From the baseline data we had found that the 
mean age of subject studied was 48.31 years (9 males 
and 2 females). The mean of values of AST, ALT and 
total bilirubin were above normal level, i.e AST 91.82 
u/L, ALT 64.64 u/L and total bilirubin 1.68 mg/dL. 
 
 
Table 1. Baseline characteristic of the study subject 
 
Parameter 
         Mean 
(x±SD) 
Range 
S e x                       ( male :female ) 9 : 2  
A g e                       ( years ) 48.31±12.80 25 – 72 
Haemoglobin        ( N ♂ = 14 -18; ♀= 12 – 16 g/dL )  12.72±2.65  6.50 – 16.30 
Platelet                  ( N 150 – 450.109/L)  210.64±52.85  117 – 308 
A S T                      (N <30 u/L) 91.82±100.16  18 – 355  
A L T                      (N <50 u/L) 64.64±49.61 16 – 165 
Total bilirubin       (N <1,30 mg/dL)  1.68±2.01 0.53 – 7.39 
Albumin                (N 4,6 – 5,4 g/dL)             4.42±0.86 2.84 – 5.49     
C r e a t i n i n e     (N 0,7 – 1,2 mg/dL) 1.27±0.77 0.58 – 2.86 
APRI Index  
1.17±1.07 0.19 – 3.17 
N = normal value   
 
The mean APRI index was 1.17 ranging from 0.19 to 3.17 
 
2. Post pentoxifylline treatment 
 In this study the AST level increased after 4 weeks pentoxifylline treatment (91.82±100.16 vs 
97.91±146.75; p=0.79), contratry to ALT and total bilirubin which decreased i.e 64.64±49.61 vs 50.64±26.13 
(p=0.28) and 1.68±2.01 vs 0.74±0.30; (p=0.008) respectively. 
 
 
 
 
 
 
 
 
Table 2. The data of mean,range pre and post 4 weeks pentoxifylline treatment  and statistic p value 
 
Parameter Pre Pentoxifylline  Post Pentoxifylline           P 
Platelet (a) 
a. Mean    (103) 
b. Range  (103) 
  
 
 
 210.64±52.85 
117 – 308  
 
 
 
207.45±57.01 
114 – 294 
 
 
0.84 
AST (b) 
a. Mean 
b. Range 
  
  
  
91,82±100.16   
18 – 355  
  
 
97.91±146.75 
22 – 490  
  
 
 
0.79 
ALT (b) 
a. Mean     
b. Range   
  
  
  
64.64±49.61 
16 – 165 
  
 
50.64±26.13  
25 – 104  
  
 
 
 
0.28 
Total bilirubin (b) 
a. Mean 
b. Range 
  
  
 
1.68±2.01  
 0.53  – 7.39  
  
 
0.74±0.30 
0.33 – 1.26 
   
 
 
 
0,008* 
Albumin (a) 
a. Mean 
b. Range 
  
 
  
4.42±0.86 
2.84 – 5.49  
  
 
 
4.69±0.52 
3.75 – 5.41 
  
 
 
 
0.37 
Creatinine(b)  
a. Mean 
b. Range 
  
 
 
1.28±0.77 
0.58 – 2.86  
  
 
1.09±0.61 
0.51 – 2.25    
   
 
 
 
0.01* 
APRI Index(b) 
a. Mean 
b. Range 
  
 
 
1.17±1.07  
0.19 – 3.17 
  
 
1.31 ±1.84 
0.23– 5.55 
 
 
 
0.96 
*Significant statistically    
 
As shown in Table 2, APRI index increased after 4 
weeks pentoxifylline treatment (1.17±1.07 vs 
1.31±1.84; p=0.96). Surprisingly, an increased of 
albumin level (4.42±0.86 vs 4.69±0.52; p=0.37) was 
observed.  
 
DISCUSSION 
 
Pentoxifyllline, 1-(5-oxohexyl)-3,7-
dimethylxanthine, is an analog of methylxanthine 
theobromine. Pentoxifylline is widely use in North 
America since 1982 to improve blood capillary 
circulation in claudicatio intermittent (Hinze et al., 
1972). Adams et al (2004) had shown that 
pentoxifylline in nonalcoholic steatohepatitis (NASH) 
at the dose 1600 mg/day for 12 months could 
decrease aminotransferase level. Satapathy et al (2004, 
2007) had shown also in NASH that ALT and AST 
had decreased after 4 weeks treatment of 
pentoxifylline 400 mg tid and still constantly 
decrease until 12 months of treatment. Contrary to 
this study, pentoxifylline could decrease ALT level 
(64.64±49.61 vs 50.64±26.13;p=0.28)  but not AST level 
(91,82 ±100.16 vs 97.91±146.75;p=0.79). The difference 
of pentoxifylline effect on ALT compare to AST is not 
quitely clear.   
Shin et al (2008) showed that APRI index was 
the most accurate indirect marker for predicting 
significant liver fibrosis in chronic hepatitis B. The 
cut-off value of APRI >1.4 has positive predictive 
value (PPV) 84% for predicting significant fibrosis 
and APRI <0.5 has negative predictive value (NPV) 
91.3% for excluding significant fibrosis. In this study, 
we found that pentoxifylline as antifibrotic agent in 
the liver didn’t decrease the APRI index score. This 
could happen because the component of APRI didn’t 
match the effect of pentoxifylline on AST and platelet 
in other previous studies.  The study of Austin AS et 
al (2004) showed that treatment of pentoxifylline with 
the dose 1800 mg once a day for 2 weeks in 12 
compensated alcoholic cirrhotic patients could 
increase platelet from 76 (56 – 131) to 80 (66 – 243).  
The study of Satapathy et al (2004, 2007) showed in 
NASH that AST were decreasing along with ALT 
after 4 weeks treatment of pentoxifylline 400 mg tid 
and still constantly decrease until 12 months of 
treatment. Contrary to this study, pentoxifylline had 
slightly decreased the platelet of chronic hepatitis B 
patients (210.64±52.85 vs 207.45±57.01; p=0.84) while 
AST increased accordingly (91.82±100.16 vs 
97.91±146.75; p=0.79). The difference observed in this 
study might be influenced by the difference of 
subjects involved in the other studies. The subjects in 
this study also showed varying APRI index range, 
from 0.19 to 3.17 revealing different stage of fibrosis. 
Whether pentoxifylline had reverse effect in 
nonsignificant liver fibrosis of chronic viral hepatitis, 
still be a question and need more study to prove. In 
this study, the use of pentoxifylline as antifibrotic 
agents in chronic viral hepatitis was not proven. 
 
Summary 
Treatment of pentoxifylline for 4 weeks as 
antifibrotic in chronic hepatitis B patients measured 
by APRI index was not proven. It might be due to 
increase of AST slight decrease of the platelet after 
treatment. More studies need to be carried out to 
prove the exact effect of pentoxifylline in liver 
fibrosis particularly in chronic viral hepatitis. In 
addition other direct and indirect biomarkers of liver 
fibrosis should be measured. 
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